AU2023222567A1 - Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin - Google Patents

Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin Download PDF

Info

Publication number
AU2023222567A1
AU2023222567A1 AU2023222567A AU2023222567A AU2023222567A1 AU 2023222567 A1 AU2023222567 A1 AU 2023222567A1 AU 2023222567 A AU2023222567 A AU 2023222567A AU 2023222567 A AU2023222567 A AU 2023222567A AU 2023222567 A1 AU2023222567 A1 AU 2023222567A1
Authority
AU
Australia
Prior art keywords
amount
subject
administering
therapeutically effective
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023222567A
Other languages
English (en)
Inventor
Jason CAMM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beren Therapeutics PBC
Original Assignee
Beren Therapeutics PBC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics PBC filed Critical Beren Therapeutics PBC
Publication of AU2023222567A1 publication Critical patent/AU2023222567A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2023222567A 2022-02-18 2023-02-17 Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin Pending AU2023222567A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263311536P 2022-02-18 2022-02-18
US63/311,536 2022-02-18
PCT/IB2023/051467 WO2023156970A1 (en) 2022-02-18 2023-02-17 Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin

Publications (1)

Publication Number Publication Date
AU2023222567A1 true AU2023222567A1 (en) 2024-09-19

Family

ID=85476260

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023222567A Pending AU2023222567A1 (en) 2022-02-18 2023-02-17 Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin

Country Status (11)

Country Link
US (1) US20240398849A1 (https=)
EP (1) EP4479064A1 (https=)
JP (1) JP2025508660A (https=)
KR (1) KR20240148426A (https=)
CN (1) CN118715017A (https=)
AU (1) AU2023222567A1 (https=)
CA (1) CA3244447A1 (https=)
IL (1) IL315046A (https=)
MX (1) MX2024010110A (https=)
TW (1) TW202342072A (https=)
WO (1) WO2023156970A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063824A2 (en) * 2002-02-01 2003-08-07 Shimoda Biotech (Pty) Ltd Pharmaceutical composition
CN1745746A (zh) * 2004-09-09 2006-03-15 天津药物研究院 冰片的羟丙基－β－环糊精包合物及其制剂和制备方法
CN1961892A (zh) * 2005-11-08 2007-05-16 天津药物研究院 降香羟丙基－β－环糊精包合物及其制剂和制备方法
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
US8975241B2 (en) * 2009-10-08 2015-03-10 Song Ho Biomed Co., Ltd. Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Also Published As

Publication number Publication date
MX2024010110A (es) 2024-08-30
US20240398849A1 (en) 2024-12-05
CA3244447A1 (en) 2023-08-24
JP2025508660A (ja) 2025-04-10
CN118715017A (zh) 2024-09-27
EP4479064A1 (en) 2024-12-25
WO2023156970A1 (en) 2023-08-24
IL315046A (en) 2024-10-01
KR20240148426A (ko) 2024-10-11
TW202342072A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
US20230330133A1 (en) Methods for the treatment of cholesterol crystal embolization with cyclodextrins
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
US20240082242A1 (en) Combination therapies
US20240398849A1 (en) Methods for the treatment of hypertriglyceridemia with cyclodextrins
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
Annecke et al. Propofol-related infusion syndrome induced by “moderate dosage” in a patient with severe head trauma
EP4203973A1 (en) Methods for the prevention of cholesterol crystal embolization with cyclodextrins
CN119157896A (zh) 烟酰胺单核苷酸用于制备预防或治疗NT-proBNP异常的药物的应用
WO2023014748A1 (en) Nitrated fatty acids for the treatment of sickle cell disorders
JPWO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤